AngioDynamics

AngioDynamics Liabilities

The The Liabilities of AngioDynamics (ANGO) as of Sep 20, 2026 is 96.34 M USD. In the previous year, The Liabilities was 97.17 M USD — a change of -0.86% (lower).

Liabilities

96.34 MUSD

YoY

-0.86%

Last updated:

In 2026, AngioDynamics's total liabilities amounted to 96.34 M USD, a -0.86% difference from the 97.17 M USD total liabilities in the previous year.

The AngioDynamics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
221.62 M USD
Jan 1, 2020
139.64 M USD
Jan 1, 2021
121.98 M USD
Jan 1, 2022
128.26 M USD
Jan 1, 2023
154.34 M USD
Jan 1, 2024
112.09 M USD
Jan 1, 2025
97.17 M USD
Jan 1, 2026
96.34 M USD
The AngioDynamics Liabilities history
YEARLiabilitiesYoY
96.34 MUSD-0.86%
97.17 MUSD-13.30%
112.09 MUSD-27.38%
154.34 MUSD+20.33%
128.26 MUSD+5.15%
121.98 MUSD-12.65%
139.64 MUSD-36.99%
221.62 MUSD+36.07%
162.88 MUSD-14.69%
190.93 MUSD-13.62%
221.04 MUSD-3.31%
228.60 MUSD-12.84%
262.26 MUSD
Access this data via the Eulerpool API

AngioDynamics Stock analysis

What does AngioDynamics do? AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics focuses on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the Vascular Access Solutions division, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary for the treatment of serious illnesses. This includes port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment options, including ultrasound-controlled radiofrequency ablation systems and fusion biopsy systems. The development of innovative diagnostic and treatment options is a focus of AngioDynamics. A majority of AngioDynamics' products are in the Peripheral Vascular Solutions division. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases such as varicose veins or chronic venous insufficiency. This includes procedures like laser and radiofrequency treatments that can be performed minimally invasively. AngioDynamics has gained an excellent reputation in the medical industry due to its high-quality products, innovative technologies, and close collaboration with medical professionals. The company places great emphasis on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Over the years, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing AngioDynamics's Liabilities

AngioDynamics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AngioDynamics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing AngioDynamics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

AngioDynamics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in AngioDynamics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about AngioDynamics stock

The Liabilities of AngioDynamics is 96.34 M USD in 2026.

The Liabilities of AngioDynamics changed from 97.17 M USD to 96.34 M USD, representing a -0.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities AngioDynamics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's AngioDynamics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — AngioDynamics

All Key Metrics — AngioDynamics